No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial

EuroIntervention 2026 Open access

Read full text
Authors: Toshiaki Otsuka, Masanori Yamamoto, Masahiko Asami, Toru Naganuma, Yohei Ohno, Tomoyuki Tani, Gaku Nakazawa, Masaki Izumo, Mike Saji, Daisuke Hachinohe, Hiroshi Ueno, Atsushi Sugiura
+10 more Tetsuro Shimura, Shinya Okazaki, Takao Morikawa, Yuki Izumi, Masaki Nakashima, Shunsuke Kubo, Shinichi Shirai, Yusuke Watanabe, Kentaro Hayashida, on behalf of the OCEAN-LAAC investigators
DOI: 10.4244/eij-d-25-01307
Cited by: 1
References: 16

Abstract

-VA score ≥2 and who successfully undergo LAAC are eligible for inclusion. A total of 500 patients undergoing LAAC will be randomised (1:1) to aspirin monotherapy versus non-antithrombotic therapy for the 45 days following OAC monotherapy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, and clinically relevant non-fatal bleeding during a maximum of 4 years of follow-up. Major bleeding or clinically relevant non-fatal bleeding is defined as Type 2, 3, or 5 bleeding, according to the Bleeding Academic Research Consortium definition. The NAPT-LAAC trial will determine the probable non-inferiority of long-term non-antithrombotic therapy to aspirin monotherapy in patients with NVAF who undergo LAAC. (ClinicalTrials.gov: NCT07125417; jRCTs031250110).

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Cardiac Valve Diseases and Treatments Coronary Interventions and Diagnostics

Publication details

Journal / source
EuroIntervention
Publisher
Europa Digital & Publishing
Volume
22
Issue
8
Pages
e455–e462
Publication date
1 April 2026
Language
EN